Impact of Aplastic Anemia on Reproductive and Mental Health
A Study on Reproductive and Psychological Health in Aplastic Anemia Patients
This study looks at how aplastic anemia and its treatments affect the reproductive and mental health of young adults aged 18-40.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Drugs / interventions | Chemotherapy, cyclophosphamide |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Trial ID | NCT06936930 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with aplastic anemia (AA) to assess the effects of the disease and its treatments on reproductive health and mental well-being. It aims to monitor sex hormone levels in male and female patients aged 18-40 years, as reproductive health issues such as irregular menstruation and infertility are common among this population. The study will evaluate how treatments like immunosuppressive therapy may contribute to reproductive impairments. By understanding these impacts, the study seeks to provide insights into the overall health challenges faced by AA patients.
Who should consider this trial
Good fit: Ideal candidates for this study are males and females aged 18-40 diagnosed with aplastic anemia and who meet specific health criteria.
Not a fit: Patients with inherited bone marrow failure syndromes or those with a history of severe psychological disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for reproductive health in patients with aplastic anemia.
How similar studies have performed: While there have been studies on reproductive health in other hematological conditions, this specific focus on aplastic anemia and its reproductive implications is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of AA * Male or female, aged 18-40 years * ECOG performance status ≤2 * Willing and able to comply with the requirements for this study and written informed consent Exclusion Criteria: * Diagnosis of inherited bone marrow failure syndromes * Combined with other hematological diseases * Chemotherapy-induced bone marrow failure * Pregnant or breastfeeding women * Subjects with a history of mental illness or severe psychological disorders * Subjects with a history of reproductive system cancer (eg, penile cancer, testicular cancer, prostate cancer, ovarian cancer, cervical cancer, vaginal cancer, etc.) * Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study
Where this trial is running
Tianjin, Tianjin Municipality
- Regenerative Medicine Center — Tianjin, Tianjin Municipality, China (Recruiting)
Study contacts
- Study coordinator: Jingyu Zhao, MPH
- Email: zhaojingyu@ihcams.ac.cn
- Phone: 13752253515
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.